Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Ascendis Pharma is a biopharmaceutical company that develops therapies to address unmet medical needs. The company focuses on developing innovative treatments using its TransCon technology platform.

Ascendis Pharma

Ascendis Pharma is applying our innovative TransCon technology platform to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we utilize our TransCon technology platform to create new and potentially best-in-class therapies.

Ascendis Pharma currently has three independent endocrinology rare disease product candidates in clinical development and we're also advancing programs in Oncology and Ophthalmology. 

Ascendis Pharma is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey.

Royalty Pharma

Sofinnova Investments

TechnoStart

Sofinnova Partners

Gilde Healthcare

OrbiMed

Venrock

Vivo Capital

RA Capital Management

Rock Springs Capital

#HCPs #AscendisPharma is so excited to attend the The MAGIC Foundation's 30th Annual Convention for families affected by growth disorders. Visit our booth to learn more about our work in pediatric #growthhormonedeficiency. #MAGICConference

Today, #AscendisPharma is acknowledging #ChronicDiseaseDay to shed light on the impact that chronic diseases have on the health and well-being of patients around the world. #hypoparathyroidism #growthhormonedeficiency #achondroplasia

Together, signatories of the Marseille Declaration are very pleased that it is working and fostering dialogue between the pharmaceutical industry and CROs, who are working together to consistently prioritize and continuously improve the welfare of all animals used in research. With #AscendisPharma as a new signatory, this coalition to improve animal welfare worldwide is growing. Merck, Novo Nordisk, Sanofi, Novartis, LEO Pharma, Lundbeck, BioReliance, EyeCRO, preclinics GmbH, NUVISAN The Science CRO #marseilledeclaration #animalresearch #3rs #animalwelfare #animalcare #biomedicalresearch

#AscendisPharma will be at the 2024 Achondroplasia & Skeletal Dysplasia Research Conference, hosted by The Chandler Project, in Baltimore this weekend. We look forward to interacting with attendees and sharing more about our work in #achondroplasia.

#HCPs Professor Ravi Savarirayan will give an oral presentation of 1-year physical functioning and well-being data from the Phase 2 ACcomplisH trial in children with #achondroplasia at the 2024 International Conference on Children’s Bone Health. The #AscendisPharma team hopes to see you there on June 24.

Our U.S. team is attending the 2024 USPHS Scientific & Training Symposium from June 24-27. We look forward to connecting with pharmaceutical industry professionals in Jacksonville. #AscendisPharma

COM:ASCENDISPHARMA

Ascendis Pharma

Last Close

122.64

22/11 21:00

Market Cap

7.78B

Beta: -

Volume Today

378.33K

Avg: -

Financials Not Available